174 related articles for article (PubMed ID: 33530812)
1. Bortezomib-loaded lipidic-nano drug delivery systems; formulation, therapeutic efficacy, and pharmacokinetics.
Mahmoudian M; Valizadeh H; Löbenberg R; Zakeri-Milani P
J Microencapsul; 2021 May; 38(3):192-202. PubMed ID: 33530812
[TBL] [Abstract][Full Text] [Related]
2. Utilization of Lipid-based Nanoparticles to Improve the Therapeutic Benefits of Bortezomib.
Korani M; Korani S; Zendehdel E; Jaafari MR; Sathyapalan T; Sahebkar A
Anticancer Agents Med Chem; 2020; 20(6):643-650. PubMed ID: 31985384
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of the intestinal absorption of bortezomib by self-nanoemulsifying drug delivery system.
Mahmoudian M; Valizadeh H; Löbenberg R; Zakeri-Milani P
Pharm Dev Technol; 2020 Mar; 25(3):351-358. PubMed ID: 31810410
[No Abstract] [Full Text] [Related]
5. Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma.
Zuccari G; Milelli A; Pastorino F; Loi M; Petretto A; Parise A; Marchetti C; Minarini A; Cilli M; Emionite L; Di Paolo D; Brignole C; Piaggio F; Perri P; Tumiatti V; Pistoia V; Pagnan G; Ponzoni M
J Control Release; 2015 Aug; 211():44-52. PubMed ID: 26031842
[TBL] [Abstract][Full Text] [Related]
6. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
[TBL] [Abstract][Full Text] [Related]
7. Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma.
de la Puente P; Luderer MJ; Federico C; Jin A; Gilson RC; Egbulefu C; Alhallak K; Shah S; Muz B; Sun J; King J; Kohnen D; Salama NN; Achilefu S; Vij R; Azab AK
J Control Release; 2018 Jan; 270():158-176. PubMed ID: 29196043
[TBL] [Abstract][Full Text] [Related]
8. Glycine-Poly-L-Lactic Acid Copolymeric Nanoparticles for the Efficient Delivery of Bortezomib.
Rajoria S; Rani S; Chaudhari D; Jain S; Gupta U
Pharm Res; 2019 Sep; 36(11):160. PubMed ID: 31520196
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib-loaded solid lipid nanoparticles: preparation, characterization, and intestinal permeability investigation.
Mahmoudian M; Valizadeh H; Zakeri-Milani P
Drug Dev Ind Pharm; 2018 Oct; 44(10):1598-1605. PubMed ID: 29874944
[TBL] [Abstract][Full Text] [Related]
10. Biotinylated HPMA centered polymeric nanoparticles for Bortezomib delivery.
Rani S; Sahoo RK; Nakhate KT; Ajazuddin ; Gupta U
Int J Pharm; 2020 Apr; 579():119173. PubMed ID: 32097684
[TBL] [Abstract][Full Text] [Related]
11. The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.
Arkwright R; Pham TM; Zonder JA; Dou QP
Expert Opin Drug Discov; 2017 Feb; 12(2):225-235. PubMed ID: 27917682
[TBL] [Abstract][Full Text] [Related]
12. Delivery of bortezomib with nanoparticles for basal-like triple-negative breast cancer therapy.
Shen S; Du XJ; Liu J; Sun R; Zhu YH; Wang J
J Control Release; 2015 Jun; 208():14-24. PubMed ID: 25575864
[TBL] [Abstract][Full Text] [Related]
13. Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations.
Liu J; Zhao R; Jiang X; Li Z; Zhang B
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053199
[TBL] [Abstract][Full Text] [Related]
14. PEGylated Dendrimer Mediated Delivery of Bortezomib: Drug Conjugation versus Encapsulation.
Sahoo RK; Gothwal A; Rani S; Nakhate KT; Ajazuddin ; Gupta U
Int J Pharm; 2020 Jun; 584():119389. PubMed ID: 32380027
[TBL] [Abstract][Full Text] [Related]
15. Synergistic anticancer activity of combined histone deacetylase and proteasomal inhibitor-loaded zein nanoparticles in metastatic prostate cancers.
Thapa RK; Nguyen HT; Jeong JH; Shin BS; Ku SK; Choi HG; Yong CS; Kim JO
Nanomedicine; 2017 Apr; 13(3):885-896. PubMed ID: 27993720
[TBL] [Abstract][Full Text] [Related]
16. Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma.
Federico C; Alhallak K; Sun J; Duncan K; Azab F; Sudlow GP; de la Puente P; Muz B; Kapoor V; Zhang L; Yuan F; Markovic M; Kotsybar J; Wasden K; Guenthner N; Gurley S; King J; Kohnen D; Salama NN; Thotala D; Hallahan DE; Vij R; DiPersio JF; Achilefu S; Azab AK
Nat Commun; 2020 Nov; 11(1):6037. PubMed ID: 33247158
[TBL] [Abstract][Full Text] [Related]
17. Enhancing the efficiency of bortezomib conjugated to pegylated gold nanoparticles: an in vitro study on human pancreatic cancer cells and adenocarcinoma human lung alveolar basal epithelial cells.
Coelho SC; Almeida GM; Santos-Silva F; Pereira MC; Coelho MA
Expert Opin Drug Deliv; 2016 Aug; 13(8):1075-81. PubMed ID: 27087021
[TBL] [Abstract][Full Text] [Related]
18. The improved anticancer effects of Bortezomib-loaded hollow mesoporous silica nanospheres on lymphoma development.
Shen J; Wang R; Wang Q; Zhang M; Liu C; Tao Z; Su G
Aging (Albany NY); 2020 Dec; 13(1):411-423. PubMed ID: 33290262
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib-Encapsulated Dual Responsive Copolymeric Nanoparticles for Gallbladder Cancer Targeted Therapy.
Chen M; Juengpanich S; Li S; Topatana W; Lu Z; Zheng Q; Cao J; Hu J; Chan E; Hou L; Chen J; Chen F; Liu Y; Jiansirisomboon S; Gu Z; Tongpeng S; Cai X
Adv Sci (Weinh); 2022 Mar; 9(7):e2103895. PubMed ID: 35068071
[TBL] [Abstract][Full Text] [Related]
20. Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib.
Tan CRC; Abdul-Majeed S; Cael B; Barta SK
Clin Pharmacokinet; 2019 Feb; 58(2):157-168. PubMed ID: 29802543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]